Lima, September 18, 2020Updated 09/18/2020 at 3:23 PM
The Ministry of Foreign Affairs reported this Thursday that the Government has signed an agreement with Pfizer and BioNTech to supply 9.9 million doses of its candidate BNT162b2 vaccine, when approved, in Peru.
According to the informationFor now, a phase 3 clinical study is underway in the United States, Germany, Argentina, Turkey and South Africa, with the aim of verifying the effectiveness of the candidate vaccine.
The candidate vaccine BNT162b2, under the evaluation regimen of two doses of 30 µg, has been developed using a messenger ribonucleic acid (mRNA) technology platform.
Coronavirus Peru LIVE
“Pfizer and BioNTech began their investigation with four candidates, of which two received ‘Fast Track’ designation from the United States Food and Drug Administration (FDA),” reported the Foreign Ministry.
He added that the agreement reached is produced thanks to the leadership of the President of the Republic, Martín Vizcarra and the coordinated work of the Ministry of Health, the Ministry of Foreign Affairs and the Embassy of Peru in the United States.
In addition, he reported this Thursday that the death toll from coronavirus (COVID-19) in the country. This is 95 new deaths compared to 31,051 on Wednesday. In addition, the entity specified that the number of infections rose to 750,098.
IT MAY INTEREST YOU